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The incidence of bleeding is increased in high risk patients with critical conditions in Intensive 
Care Unit (ICU). Appropriate prophylaxis medicine is necessary to reduce the incidence of stress ulcer 
bleeding during hospitalization in ICU which further can minimize the cost of patient care in the ICU. 
Currently, lansoprazole and pantoprazole are used as a stress ulcers prophylaxis. Nevertheless, there 
has not been sufficient evidence proving their effectiveness. This study was aimed to compare the 
effectiveness and cost between iv lansoprazole and iv pantoprazole as a stress ulcer prophylaxis in 
ICU. In this retrospective observational study, the data were obtained from medical records of all 
patients admitted to ICU in a District Hospital in Yogyakarta from January 2014 until December 2016. 
Effectiveness of therapy were obtained from objective data in the medical record by looking at the 
incidence of major (clinically significant) and minor (overt gastrointestinal) bleeding. Chi-square 
analysis was performed to analyze the difference of bleeding incidence. The average cost was 
presented as Expected Monetary Value (EMV), which consisted of the cost of prophylaxis and 
treatment of bleeding. The difference in average cost was analyzed using independent t-test. A total of 
119 patients were included in this study. There were 62 patients in the lansoprazole group and 47 
patients in the pantoprazole group. Forty eight patients (77.4%) from lansoprazole group and 35 
patients (61.4%) from pantoprazole group did not experience any GI bleeding. There was no statistical 
difference in the incidence of GI bleeding between the two groups (CI 95%, P-value = 0.057). The 
EMV of lansoprazole group was higher than pantoprazole group IDR 645.122.57 and IDR 511.629.39 
respectively. In conclusion, there was no significant difference regarding the effectiveness between iv 
lansoprazole and iv pantoprazole as stress ulcer prophylaxis. Costs for the prophylaxis of stress ulcers 
is lower on the use of pantoprazole compared to lansoprazole. 
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Patients with critical conditions treated in ICU  are at risk of developing stress ulcers. Stress 
ulcers have been reported to increase morbidity and mortality. Previous study had proven that 
extending the length of stay for 4 and 8 days was associated with an increase in mortality up to 4 
times. An endoscopic observation revealed that most of ICU patients (75% - 100%) experienced 
gastric mucosal disorder a few hours after being admitted to ICU (Burris, 2014; Mutlu et al., 2001; 
Yazdi and Imantalab, 2015). Another evidence proved that 35 -100% of ICU patients showed positive 
results in stomach acid test, which is indicated by bleeding event (Spirt and Stanley, 2006). 
American Society of Health-System Pharmacists (ASHP) Guideline states that stress ulcer 
prophylaxis should be prescribed only for high-risk patients, especially for patients in the Intensive 
Care Unit (ICU). Proton pump inhibitors (PPIs) and histamine-receptor antagonists (H2RA) are 
prescribed widely to prevent stress ulcers in clinical practice (ASHP, 1999; Mohamad et al., 2015). 
Some studies had suggested that PPIs were demonstrably superior and  less costly as a stress ulcer 
prophylaxis compared to H2RA (Barkun et al., 2013; Udeh et al., 2010). 
PPIs were frequently prescribed in ICU for various indications, predominantly for stress ulcer 
prophylaxis. Such indication accounted for 47% of total PPIs prescription in ICU, while the rest of 
20% and 11,5% were indicated for gastrointestinal bleeding and peptic ulcer disease medication, 
respectively (Heidelbaugh et al., 2010). Administration of PPIs as stress ulcer prophylaxis during 
inpatient care may affect the total cost of treatment in ICU. 
Currently, lansoprazole and pantoprazole, the newer generation of PPIs, are used as a stress 
ulcers prophylaxis. Nevertheless, there has not been sufficient evidence proving their effectiveness as 
a stress ulcers prophylaxis compared to older generation, such as omeprazole. Lansoprazole proposed 
several advantages over pantoprazole. Although classified in the same class, both agents did not share 
a similar pharmacokinetic profile which may influence their effectiveness. Lansoprazole reaches 
maximum concentration faster and provides greater bioavailability than lansoprazole as well. 
However, lansoprazole has a greater clearance compared to pantoprazole (Chubineh and Birk, 2012; 
Shin and Kim, 2013). Beside that, according to Udeh et al. (2010), lansoprazole required lower 
acquisition cost per dose in comparison with pantoprazole. Therefore, choosing lansoprazole will be 
more beneficial in limited healthcare resource conditions. 
 Although lansoprazole and pantoprazole had been studied previously by Udeh et al. (2010), 
there were several differences regarding route of administration, research site, and patient condition. 
Considering the urgency of preventing stress ulcers in high risk patients, increasing demand in 
minimizing treatment cost, and emerging fact that newer generation of PPIs are frequently prescribed 
(including lansoprazole and lansoprazole), it is necessary to evaluate the costs and effectiveness of 
newer generation PPIs. This research was aimed to observe whether there were differences in the 
effectiveness and cost of using lansoprazole and pantoprazole therapy as stress ulcer prophylaxis. 
 
MATERIALS AND METHOD  
We conducted a retrospective cohort study of ICU patients receiving 30 mg lansoprazole given 
intravenously once daily (Takeda, Prosogan®, city, state, Indonesia) or 40 mg pantoprazole generic 
given intravenously once daily as a stress ulcers prophylaxis at Hospital in Yogyakarta. This study was 
approved by Ethics  Committee (approval number : 00527 / KKEP / FKG-UGM / EC / 2016), Faculty 
of Medicine, Universitas Gadjah Mada, Indonesia.  
 
Population 
The study population comprised patients admitted to ICU and received lansoprazole or 
pantoprazole as a stress ulcer prophylaxis. Patients were eligible for this study if they fulfilled 
inclusion criteria as follow : (1) Adult patient, ≥18 years - 65 years old, having at least one of the 
following risk factors (a) Use of mechanical ventilation > 48 hours, (b) Coagulopathy (INR> 1.5; PTT 
> 2x controls; Platelet <50 thousand) and two factors risk of (a) Hypotensive shock, (b) Sepsis shock, 
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(c) Liver failure / kidney failure / heart failure, (d) spinal cord injury, (e) Liver/kidney transplantation, 
(f) Burns> 35% body surface area, (g) Trauma: Post-major, post-natal, post chemotherapy, (h) Head 
Injury (GCS ≤ 10), (i) History of gastric ulceration / bleeding in 1 year before entering the hospital, (j) 
ICU Stay> 1 week, (k) Corticosteroid therapy (> 250 mg or similar); (2) Received lansoprazole or 
pantoprazole for at least 1 day or 24 hours during the hospitalization in the ICU. Patients were 
excluded if they received a combination of gastric acid suppressants therapy other than pantoprazole 
and lansoprazole or if they were diagnosed with any of these conditions : hematemesis, melena, 
gastritis or ulcer when admitted to ICU. 
 
Data collection 
Data were obtained from patient medical records and hospital billing system between January 
2014 and December 2016. Following data were retrieved from patient medical records: (1) Patient 
diagnoses at admission and during hospitalization in ICU, (2) patient characteristics such as type sex, 
age, length of stay, GCS scale, type and number of risk factors, (3) agent used for stress ulcers 
prophylaxis, including dose and route of administration (4) Any medication to treat other underlying 
disease or comorbid (5) presence/absence of bleeding (overt gastrointestinal bleeding /minor bleeding 
and clinically significant gastrointestinal bleeding/major bleeding). 
Medication costs were retrieved from the hospital billing system. Medication cost consisted of 
drug and non-drug costs directly related to stress ulcer prophylaxis and management of ulcer/bleeding. 
Components of drug costs consisted of prophylaxis drug costs (lansoprazole and pantoprazole) and 
drug costs to cure bleeding events such as sucralfate, vitamin K, tranexamic acid, and parenteral 




The clinical outcome of the analysis was gastrointestinal bleeding events. Stress ulcer 
prophylaxis was considered a success if the patient did not experience either overt gastrointestinal 
bleeding or clinically significant bleeding. Overt gastrointestinal bleeding/minor bleeding was 
characterized by hematemesis, melena, hematochezia or reddish/blackish-brown residue inside the 
nasogastric tube (NGT). While clinically significant bleeding/major bleeding was defined as 
occurrence of minor bleeding followed by at least one condition : systolic or diastolic blood pressure 
suddenly fell 20 mmHg or more within 24 hours of bleeding, started using vasopressor or increased 
vasopressor dose by 20%, decrease hemoglobin (Hb) level at least 2 g/dL, needed transfusion of 2 
units of PRC or more (Krag et al., 2016). The economic outcome was the average cost for each 
treatment group. The average costs were presented as Expected Monetary Value (EMV). EMV was 
calculated for both treatment groups.  
 
Analysis 
Chi-Square test was used to analyse effectivity of stress ulcer prophylaxis. Cost analysis were 
carried out by looking at the details of medication costs directly on patients receiving care at the ICU. 
A decision tree scheme was constructed to present the costs of lansoprazole versus pantoprazole 
during the hospitalization in ICU. In each treatment group, patients were categorized into those 
experiencing bleeding and those without bleeding. EMV was calculated by multiplying an outcome 
probability in specific treatment group and the costs related to the outcome. Independent t-test was 
performed to compare the average cost between the two groups. SPSS 22 was used to perform 
statistical analysis. A two-tailed P-value of 0.05 was considered statistically significant in this study. 
 
RESULT AND DISCUSSION 
Patient Characteristics  
From the beginning of the study, it was discussed that lansoprazole and pantoprazole were 
chosen because they were the most widely used PPIs class in ICU. A total of 119 patients met 
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eligibility criteria and were included in the analysis, of whom divided into 62 patients in the 
lansoprazole group and 57 patients in pantoprazole. The baseline characteristics of 119 patients 
included sex, length of stay in ICU, Glasgow Coma Scale (GCS) scale, the total of risk factors, and the 
type of bleeding risk factors during the hospitalization in ICU are shown in Table 1.  
 
Table 1. Characteristics of patients with high risk of bleeding in ICU 
Characteristic 
Patients (n=119) 





   Man 










   18-30 
   31-40 











Age (mean ± SD) 57.26 ± 9.243 55.98 ± 9.539 0.220 
ICU Stay (day) 
  ≤ 7 










  ≤ 10 









Number of Risk Factors        
  1-2 
  3-4 












   CHF 
   Sepsis 
   CKD 
   Corticosteroid use 
   Trauma 
   Coagulopathy 
   Mechanic ventilator 
   HF 
   Hipotension 


































*statistically significant (P≤0.05) 
GCS  : Glasgow Coma Scale  
CHF  : Chronic heart failure 
CKD : Chronic kidney Disease 
HF    : Heart Failure 
 
Most of the characteristics between the two groups were balanced, except length of stay, number 
of risk factors, and sepsis (P≤0.05). Most patients in both groups stayed in ICU for less than 7 days. 
However, the proportion of those who stayed in ICU for less than 7 days in the pantoprazole group 
was higher than lansoprazole group. Patients in the pantoprazole group seemed to have more risk 
factors than those in the lansoprazole group. Patients in the pantoprazole group predominantly had 
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more than 2 risk factors. Furthermore, there were more patients who suffered from sepsis in the 
pantoprazole group than those in the lansoprazole group. 
 
Ulcerogenic drug use profile 
During treatment at the ICU, the patient received medications to overcome medical problems. 
Of the drugs received by the patients, there were ulcerogenic drugs. These drugs are well known for 
their potency to induce gastrointestinal bleeding (Yasuda et al., 2015). The researcher would 
emphasized the use of stress ulcer prophylaxis drugs and ulcerogenic drugs. The proportion of 
ulcerogenic drugs prescribing between the two groups are illustrated in Table 2. 
 
Table 2. Comparison of the number of patients receiving ulcerogenic drugs between the 
lansoprazole group and pantoprazole group 
Ulcerogenic agent Lansoprazole pantoprazole P-value 
Corticosteroid 21 20 0.889 
Analgesic NSAIDs 21 24 0.355 
Antiplatelet 26 26 0.686 
Anticoagulant 10 8 0.750 
 NSAIDs : Non Steroid Anti-Inflammation Drugs 
 
Several types of ulcerogenic drugs in this study were corticosteroid (prednisolone and 
dexamethasone), Nonsteroidal Anti-inflammatory Drugs/NSAIDs (antalgic injection (Sanofi Aventis, 
Novalgin®, ketorolac and diclofenac potassium), antiplatelet (aspirin and clopidogrel) and 
anticoagulant (fondaparinux sodium). (Tambahkan referensi bahwa obat-obat ini bersifat ulserogenik)  
It could be inferred from the table that the proportion of ulcerogenic drugs prescribing in both groups 
was well balanced and proven statistically (P>0.05). 
 
Clinical outcome 
The patient medical record was used in order to observe the bleeding incidence encountered by 
the patients during their hospitalization in ICU. The proportion of patients experiencing minor and 
major bleeding events  in the ICU are illustrated in Table 3 below. 
  









lansoprazole 48 (77.4) 1 (1.6) 13 (21) 
0.057 
pantoprazole 35 (61.4) 5 (8.8) 17 (29.8) 
 
As mentioned in Table 3, fewer patients had minor or major bleeding when lansoprazole was 
used as a stress ulcer prophylaxis. A total of 48 of 62 patients (77.4%) in the lansoprazole group did 
not experience bleeding and 35 of 57 (61.4%) patients in the pantoprazole group did not experience 
bleeding. According to statistical analysis, it could be interpreted that there was no difference 
regarding effectiveness of lansoprazole and pantoprazole as a stress ulcer prophylaxis (P=0.057) even 
though a higher percentage of both major and minor bleeding was observed in pantoprazole group. 
Thus, we also examined the other factors to find out what might influence the clinical outcome. 
Several factors affecting the effectiveness difference between lansoprazole and pantoprazole 
in preventing bleeding incidence did exist in this study. This difference was due to some of the patient 
characteristics proportions mentioned in Table 1, such as length of stay, sepsis, the number of risk 
factors and ulcerogenic drugs. Table 4 shows the association between these characteristics and 
bleeding events. 
                ISSN: 2088 4559; e-ISSN: 2477 0256 






Table 4. Effect of patient characteristics on bleeding events 






    - > 7 days 















    0.065 
Number of Risk factors 
-     1-2 
-     3-4 












-     Kortikosteroid 
-     NSAIDs 
-     Antiplatelet 












    0.556 
    0.326 
0.007* 
    0.055 
*Statistically significant (P value ≤0,050) 
NSAIDs  : Non Steroid Anti-Inflammation Drugs 
 
According to Table 4, the length of stay in ICU and the number of risk factors had a P-value 
<0,05. Therefore it could be concluded that length of stay in ICU and number of risk factor 
significantly predisposed the clinical outcome (bleeding occurrence) (P value=0.001 and P 
value=0.030 respectively), whereas sepsis had no effect on the clinical outcome. 
In this study, the length of stay in ICU was categorized into those who stayed in ICU for less 
than 7 days and those who stayed in ICU more than 7 days. A higher incidence of bleeding was 
reported in patients whose length of stay was more than 7 days. Therefore, extending the length of stay 
in ICU until more than 7 days was related to increased risk of bleeding (P=0.001). These findings was 
consistent with the result of a former study conducted by Khoshbaten et al. (2006) and Kerama et al. 
(2014),. This study stated that the average length of stay of those who experienced major bleeding 
(26,67% of total patients observed) was longer than those without major bleeding. In addition, Reyes 
and Ramírez (2014) and Mohebbi  (2009) stated that the length of stay more than 7 days in ICU were 
associated with a high risk of bleeding. Therefore, the magnitude of bleeding incidence in the 
pantoprazole group was possibly affected by a high proportion of patients staying in ICU for more 
than 7 days. 
Major and minor risk factors were never found separated with any patient condition in ICU. 
During the study, the subjects, on average, had 2-4 risk factors each patient. The researcher classified 
the patients into 3 categories based on the number of risk factors. According to Table 4, it could be 
inferred that the more risk factors the patients had, the higher the percentage of bleeding event. This 
association was proven with statistically significant (P=0.030). Thus, further subgroup analysis was 
necessary to ensure the impact of stress ulcer prophylaxis type and bleeding event in each level of risk 
factor. 
In this study, Sepsis had no effect on the increased risk of gastrointestinal bleeding. This is 
different with the research conducted by Yang et al. (2018), which stated that sepsis is an important 
risk factor for gastrointestinal bleeding in patients with acute coronary syndrome (ACS). 
Some patients from both lansoprazole and pantoprazole groups were treated using medicines 
that might affect the incidence of gastric bleeding. Table 4 shows the effect of the use of ulcerogenic 
medicines on bleeding events in patients treated with lansoprazole and pantoprazole. 
According to Table 4, the sum of patients experiencing bleeding was higher than those without 
bleeding regardless of the type of the ulcerogenic drugs. Based on statistic analysis, most of the 
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ulcerogenic drugs did not significantly affect bleeding event except antiplatelet (P=0.007). Similar 
finding was established in a study conducted with Pipilis et al. (2014). This research stated that the use 
of antiplatelet, as well as increasing age, was one of gastrointestinal bleeding risk factors. Another 
research found that a dose-dependent gastrointestinal bleeding was related to the use of aspirin. The 
risk of gastrointestinal bleeding event was doubled if 300 mg aspirin was administered as an 
antiplatelet (Lanas et al., 2006). However, the proportion of antiplatelet drug prescription between the 
two groups was not significantly different (P-value = 0.587) so that both groups had the same bleeding 
risk due to antiplatelet use. 
 
Economic outcome 
Cost analysis was carried out by directly looking at the details of medical costs of patients 
treated in ICU. Each of stress ulcer prophylaxis and ulcer/bleeding costs was a combination of drug 
and non-drug components. Drug costs represented prophylaxis drug costs (lansoprazole and 
pantoprazole) and drug costs to cure bleeding events such as sucralfate, vitamin K, tranexamic acid, 
and parenteral nutrition. Meanwhile, non-drug costs component included the cost of medical devices 
such as syringes and transfusion costs. The difference in the average cost required in the therapy 
groups of lansoprazole and pantoprazole can be seen in the Table 5. 
 
Tabel 5. The difference in the average cost required in the therapy groups of lansoprazole and 
pantoprazole in ICU 
Cost Average Cost ±SD (Rp) P Value 
Lansoprazole (n=62) Pantoprazole (n=62) 
 Prophylaxis drug costs  IDR573,181.52 ± 224,427.21  IDR 284,280,93 ± 160,843.74    0.000* 
 Medical Device Cost  IDR 17,409.52 ± 6,816. 62  IDR 22,188,95 ± 12,494.63    0.011* 
            Subtotal  IDR 590,591. 05 ± 231,243. 83  IDR 306,469,88 ± 173.160,51  
 Drug costs to cure bleeding  
events 
 IDR 219,895. 64 ± 239,834.63  IDR 345,594,23 ± 583,148.27    0.935 
 Non-drug costs to cure 
bleeding events 
 IDR 27,229.09 ± 19,442. 40  IDR 240,585. 71 ± 480,260. 86    0.268 
           Subtotal  IDR 241,289.93 ± 246.883.13  IDR 531,501.36 ± 785,204.79  
*    = Significant Different 
SD = Standart Deviation 
  
The average costs in this study consisted of stress ulcer prophylaxis cost and treatment of 
ulcer/bleeding costs in ICU. The average cost was represented with EMV. The average costs required 
in the lansoprazole and pantoprazole group are explained in Figure 1. 
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Figure 1: Expected monetary value 
 
This study suggested that the EMV of lansoprazole group was higher than pantoprazole group 
(IDR 645,122.57 and IDR 511,629.39 respectively). However, the difference was not statistically 
significant. More detailed observation found that the cost of bleeding outcome in the pantoprazole 
group was higher than that of lansoprazole. But the opposite result was found in non-bleeding 
outcome. 
Prophylaxis drug cost between lansoprazole and pantoprazole group 
(IDR573,181.52±224,427.21 and IDR 284,280.93±160,843.74 respectively) was significantly different 
according to statistical analysis (P value=0.000). Higher prophylaxis drug cost was observed in the 
lansoprazole group. The difference in the average of prophylaxis drug costs was mainly due to 
different drug prices. Prosogan® injection, the patent drug of lansoprazole, was used in the 
lansoprazole group. Whereas, generic drug was used in pantoprazole group. Consequently, 
administering patent drug of lansoprazole require a greater average prophylaxis drug costs than 
generic pantoprazole. 
The length of stay was possibly might affect the costs required by patients during the treatment 
period in the ICU as well. The longer the patient treated in ICU, the greater the costs required 
(Aygencel and Turkoglu, 2011). According to Table 1, the proportion of patients' length of stay 
between the two groups was not balance and proven statistically (P-value = 0.007). Length of stay 
more than 7 days certainly greatly affected the average prophylaxis drug costs in the pantoprazole 
group. Nevertheless, as mentioned before, the average prophylaxis drug cost in the pantoprazole 
therapy group was much lower than the lansoprazole group. This finding ensured that the influence of 











Cost Rp831.880,98 x 0,226 = 
IDR188.005,10 
Cost Rp590.591,05 x 0,774 = 
IDR457.117,47 
Cost Rp837.971,24 x 0,386 = 
IDR323.456,89 











Patients in ICU 
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The cost of prophylaxis medical device represented the cost of syringes used for administering 
prophylaxis drug injections. The 10 cc syringe was used in this study for both lansoprazole and 
pantoprazole group. Patients in the lansoprazole group required a lower average cost of prophylaxis 
medical device than those in the pantoprazole group (IDR17.409,52±6.816,62 and 
IDR22.188.95±12.494.63). This finding was supposedly related to the number of prophylaxis medical 
device, which was directly proportional to the total number of prophylaxis drugs administered during 
the treatment period in ICU. One factor affecting the number of prophylaxis drugs needed by the 
patients was the length of stay (Aygencel and Turkoglu, 2011). The longer the patient treated in ICU, 
the greater the number of prophylaxis drug required. As mentioned before in Table 1, the proportion of 
patients who stay in ICU for more than 7 in the pantoprazole group was greater than that of the 
lansoprazole group (43.9% and 21% respectively) so did the number of medical devices required in 
pantoprazole group. 
Bleeding costs in this study comprised the cost of drugs used to treat gastrointestinal bleeding 
and the cost of drugs for post-bleeding side effects. The drugs used to treat gastrointestinal bleeding 
consisted of sucralfate, tranexamic acid, and vitamin K. While the drugs used manage post-bleeding 
side effects were any drugs/treatment indicated for post-bleeding side effects such as blood pressure 
fell drastically or impaired food absorption causing the need for parenteral nutrition. The average 
bleeding cost in pantoprazole group was IDR531.501.36±785.204.79. While lower cost was required 
in the lansoprazole group (IDR 241.289.93±246.501.36). As mentioned before in Table 1, a higher 
proportion of those who experienced bleeding was observed in the pantoprazole group. Therefore, this 
finding could explain why it required higher cost to manage bleeding in the pantoprazole group. 
Moreover, the severity of bleeding might influence the average cost of bleeding as well. There were 
more patients experiencing major bleeding in the pantoprazole group than lansoprazole group. Further 
statistic analysis on drug and non-drug cost of both groups showed that neither the drug cost nor the 
non-drug cost between 2 groups was different significantly. 
 
Research Limitation 
Researchers could not control the factors that could affect the effectiveness of therapy, such as 
the number of comorbid and ulcerogenic drugs. Length of stay is not only caused by gastrointestinal 
bleeding but is influenced by the main diagnosis 
 
CONCLUSION 
There were 77.4% of patients in the lansoprazole group who did not experience bleeding, 
whereas 61.4% of patients in the pantoprazole group did not experience bleeding. The effectiveness 
difference of lansoprazole and pantoprazole as a stress ulcer prophylaxis in ICU was not statistically 
significant (P-value >0.05). Costs for the prophylaxis of stress ulcers is lower on the use of 
pantoprazole compared to lansoprazole. Further research is needed using 2 groups that are equally 
homogeneous so that the research results can be used for decision making. 
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